What cardiovascular and metabolic effects were observed in the study of patients with heart failure and 48-hour glucagon-like peptide-1 infusion?
The study of Halbirk et al. (2020) found that 48-hour glucagon-like peptide-1 infusion in compensated chronic patients with heart failure led to improved cardiac function, reduced heart rate and blood pressure, improved glucose tolerance, and increased insulin sensitivity. Additionally, there was a decrease in levels of circulating hormones associated with cardiac remodeling and disease progression, such as aldosterone and endothelin-1. Overall, this study suggested that glucagon-like peptide-1 infusion could be beneficial in reducing the symptoms of heart failure. 